Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

Located in midtown Manhattan and designed by SHoP Architects, the 1,428-foot-high skyscraper is the second tallest ...

The key to Sanofi becoming a pure biopharma player: investment. A year later, the French company announced the divestment of ...

Adults in their 30s are at risk of developing metabolic-associated fatty liver disease (MAFLD) due to metabolic changes in ...

Jobs — and national identity — top French concerns over the news that pharmaceutical company Sanofi plans to sell 50% of ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Q3 Non-GAAP EPS of €2.25. Revenue of €13.44B (+12.3%) Q3 sales growth of 15.7% at CER and business EPS of €2.86; 2024 business ...